Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

52 results about "Colon cancer tumor" patented technology

Hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit and preparation method and detection method thereof

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.
Owner:HANGZHOU HUIYUANTAI MEDICAL DEVICES

Application of rhizopus nigricans exopolysaccharides in preparation of medicine for treating or preventing gastrointestinal tumors

The invention relates to an application of rhizopus nigricans exopolysaccharides in preparation of a medicine for treating or preventing gastrointestinal tumors. The method for preparing the rhizopus nigricans exopolysaccharides comprises the following steps: (1) activating and performing fermental cultivation on rhizopus nigricans with a strain collection number of CGMCC NO.8436, and preparing fermentation liquor; (2) separating and purifying the fermentation liquor, and preparing a crude extracting solution; and (3) discoloring the crude extracting solution by resin columns, oscillating to remove proteins through a Seveage reagent, performing column chromatography purification on Sephadex G-50 sephadex, and preparing the rhizopus nigricans exopolysaccharides. An animal tumor model is established by utilizing the rhizopus nigricans exopolysaccharides, the tumor activity of an entity anti-alimentary system of the rhizopus nigricans exopolysaccharides is explored, the animal tumor experiment anti-tumor result proves that the rhizopus nigricans exopolysaccharides can obviously inhibit growth of tumor blocks of stomach cancer tumor mice and colon cancer tumor mice, and when the rhizopus nigricans exopolysaccharides are combined with modern chemotherapy drug cyclophosphamide, the anti-tumor curative effect is obviously higher than the anti-tumor effect of a single cyclophosphamide drug.
Owner:SHANDONG UNIV

Application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of chemotherapeutic drug combined with trichoderma pseudokoningii exopolysaccharide in treating colon cancer

The invention discloses application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of a chemotherapeutic drug combined with the trichoderma pseudokoningii exopolysaccharide in treating the colon cancer. The trichoderma pseudokoningii exopolysaccharide (EPS) can significantly inhibit the growth of tumor masses in a mouse with the colon cancer, and can improve mouse immune organ index and the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum, increase the proportion of mouse cytotoxic T lymphocytes (CD8+T cells) in total T lymphocyte calculation and significantly activate mouse T lymphocytes and B lymphocytes; therefore, the EPS has an effect on treating the colon cancer; and the EPS, when taken for a preventive purpose, can also effectively improve the antitumor capacity of a body. In addition, the EPS, when combined with an existing chemotherapeutic drug, namely 5-fluorouracil (5-FU), is significantly better than the single medication of the 5-FU in antitumor effect. Moreover, the EPS can improve the life quality of the mouse with the colon cancer and can prolong the service life of the mouse.
Owner:WANNAN MEDICAL COLLEGE

The application of Trichoderma pseudoconii exopolysaccharide in the treatment and prevention of colon cancer, and its application in combination with chemotherapy drugs in the treatment of colon cancer

The invention discloses application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of a chemotherapeutic drug combined with the trichoderma pseudokoningii exopolysaccharide in treating the colon cancer. The trichoderma pseudokoningii exopolysaccharide (EPS) can significantly inhibit the growth of tumor masses in a mouse with the colon cancer, and can improve mouse immune organ index and the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum, increase the proportion of mouse cytotoxic T lymphocytes (CD8+T cells) in total T lymphocyte calculation and significantly activate mouse T lymphocytes and B lymphocytes; therefore, the EPS has an effect on treating the colon cancer; and the EPS, when taken for a preventive purpose, can also effectively improve the antitumor capacity of a body. In addition, the EPS, when combined with an existing chemotherapeutic drug, namely 5-fluorouracil (5-FU), is significantly better than the single medication of the 5-FU in antitumor effect. Moreover, the EPS can improve the life quality of the mouse with the colon cancer and can prolong the service life of the mouse.
Owner:WANNAN MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products